 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...1112131415161718192021...3839» |
- || Clinical, Journal: Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. (Pubmed Central) - Sep 2, 2021
After >12 months of follow-up, more patients with rheumatoid arthritis receiving etanercept remain on treatment compared with other TNFi.
- | Journal, HEOR: Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. (Pubmed Central) - Sep 2, 2021
TNF-α's appeared more effective than IL-12/23's for biologic-naïve individuals, and PDE4's for biologic-experienced individuals. These results may help inform treatment choice for individuals with PsA.
- | Orencia (abatacept) / BMS, Kineret (anakinra) / SOBI, Cimzia (certolizumab pegol) / Astellas, UCB
تداخلات دارویی سرتولیزومب پگول تداخلات دارویی: اثرات متابولیسمی/ انتقالی: نامشخص عدم استفاده همزمان: از استفاده همزمان Certolizumab با این داروها اجتناب کنید: Abatacept؛ Anakinra؛ دوز دوم واکسن کرونا به خیلی ها زده شده @merck (Twitter) - Aug 25, 2021
- || Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Vasculitis During Certolizumab Pegol and Secukinumab Treatment: Report of Two Cases. (Pubmed Central) - Aug 25, 2021
These results may help inform treatment choice for individuals with PsA. No abstract available
- || Cimzia (certolizumab pegol) / Astellas, UCB
Cimzia would be great if she failed SFZ and HCQ b4 (Twitter) - Aug 23, 2021
- || Biomarker, Review, Journal: Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review. (Pubmed Central) - Aug 20, 2021
In a systematic review of 10 studies, we found evidence for consistent changes in microbiomes of fecal and colon samples from patients with IBD who responded to treatment with biologic agents. Prospective studies are needed to determine what changes are significantly associated with treatment, whether these changes are causes or effects of response, or whether the composition of the intestinal microbiome can be used to select treatments for patients with IBD.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Review, Journal: Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis. (Pubmed Central) - Aug 20, 2021
Based on a meta-analysis of data from randomized trials of anti-TNF therapies in patients with active CD, patients receiving corticosteroids during induction therapy with anti-TNF agents did not have higher rates of clinical improvement compared with patients not receiving corticosteroids during induction therapy. Given these findings and the risks of corticosteroid use, clinicians should consider early weaning of corticosteroids during induction therapy with anti-TNF agents for patients with corticosteroid-refractory CD.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Optimization of culture conditions for high-level expression of soluble and active tumor necrosis factor-α in E. coli. (Pubmed Central) - Aug 20, 2021
Binding kinetics were also studied using Cimzia as an anti-TNF-α molecule and 7.2 EM was calculated as the equilibrium dissociation constant value (K). The significant expression level of the recombinant protein in the soluble form, its high purity, and assessment of its biological activity showed that the expressed protein could be used in tests of ELISA and MTT to assess the activity of anti-TNF-α agents.
- || Retrospective data, Review, Journal: Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis. (Pubmed Central) - Aug 19, 2021
Reduction or spacing biologics did not affect disease activity and other important outcome. Changes in the doses regimen should consider patient preferences, considering the low certainty of evidence.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: CHERISH: A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (clinicaltrials.gov) - Aug 18, 2021
P1b, N=20, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Changes in the doses regimen should consider patient preferences, considering the low certainty of evidence. Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
- || Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial. (Pubmed Central) - Aug 15, 2021
P4
Pre-treatment IFNα positivity did not predict remission in any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815 .
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Differential impacts of TNFα inhibitors on the transcriptome of Th cells. (Pubmed Central) - Aug 15, 2021
A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, https://clinicaltrials.gov/ct2/show/NCT01491815 . TNFis can have drug-specific effects on the transcriptional profile of Th cells.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Understanding covalent and non-covalent interactions during in-vitro refolding of antibody fragments (Fab) (Room: Zoom Room 04) - Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_9228;
Two model antibody fragments (Biosimilar rHu Ranibizumab and rHu Certolizumab) were expressed as inclusion bodies using E. coli host...We conclude that compared to non-covalent interactions, covalent interacttions majorly drive the in-vitro refolding rates of antibody fragments. We also conclude that ETD can provide significant alternative fragmentation information that complements CID-derived data to improve the disulfide bond mapping during in-vitro refolding of multidomain proteins like antibody fragments.
- || Retrospective data, Review, Journal: Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. (Pubmed Central) - Aug 8, 2021
The most commonly reported reaction is psoriasis/psoriasiform reaction. Clinicians should be vigilant to dermatological side effects following treatment of IBD with anti-TNF.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Impact of a risk-sharing agreement in rheumatoid arthritis in Spain. (Pubmed Central) - Aug 6, 2021
Clinicians should be vigilant to dermatological side effects following treatment of IBD with anti-TNF. RSA implementation on patients with RA treated with CZP has generated savings and improved efficiency within HPS.
- | Opdivo (nivolumab) / BMS, Cimzia (certolizumab pegol) / Astellas, UCB
New P2 trial: Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (clinicaltrials.gov) - Aug 4, 2021
P2, N=60, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: P.S. I would have been very keen to get involved in the study, but I’m on Certolizumab and also had my second vaccine in March 🙈 (Twitter) - Aug 4, 2021
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study. (Pubmed Central) - Aug 4, 2021
RSA implementation on patients with RA treated with CZP has generated savings and improved efficiency within HPS. This first study on a modern treatment approach in pregnant patients with RA shows that LDA and remission are an attainable goal during pregnancy, with 90.4% of patients achieving this in the third trimester.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. (Pubmed Central) - Aug 1, 2021
These values are critical in the decision making process. More studies are needed to address the value of such measurements for non-anti-TNF biologics.
- | European regulatory, Journal: The pre- and post-authorisation data published by the European Medicines Agency on the use of Biologics during pregnancy and lactation. (Pubmed Central) - Jul 30, 2021
In this article several suggestions are provided for improving a multidisciplinary approach to these issues. The initiation of suitable registries by marketing authorization holders and data transparency for clinicians and academics, are highly endorsed.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal, HEOR: An Economic Analysis of the Impact of Homecare Drug Administration for Biologic Interventions Available for Plaque Psoriasis in the UK. (Pubmed Central) - Jul 29, 2021
These results indicate that drug administration costs are meaningful and should be given greater consideration in the selection process of treatments for plaque psoriasis. Additionally, the NHS could save money by paying for drugs to be delivered to a patient's home, rather than administering them in a hospital setting.
- [VIRTUAL] Screening and monitoring of TB infection in rheumatological patients on biologics therapy () - Jul 29, 2021 - Abstract #ERS2021ERS_2860;
Conclusion. Rheumatological patients need both screening and monitoring TB infection.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Journal, HEOR: An Economic Analysis of the Impact of Homecare Drug Administration for Biologic Interventions Available for Plaque Psoriasis in the UK. (Pubmed Central) - Jul 28, 2021
These results indicate that drug administration costs are meaningful and should be given greater consideration in the selection process of treatments for plaque psoriasis. Additionally, the NHS could save money by paying for drugs to be delivered to a patient's home, rather than administering them in a hospital setting.
- [VIRTUAL] HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4583;
Knowledge of disease distribution may also have a role in predicting subsequent LOR. Future research should focus on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors.
- [VIRTUAL] EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND AN INDIVIDUAL-PATIENT DATA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4537;
In this individual-patient-data meta-analysis of randomized controlled trials with multiple biologics, there were higher rates of induction-of-remission both with biologics and with placebo in early CD, resulting in a treatment-to-placebo effect ratio which is similar across disease durations. No relationships between disease-duration and outcomes was found in UC.
- [VIRTUAL] FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4532;
DI requirement is higher in UC patients and in those with prior anti-TNF exposure. Empirical DI is a relatively effective therapeutic option.
- [VIRTUAL] HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2403;
Knowledge of disease distribution may also have a role in predicting subsequent LOR. Future research should focus on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors.
- [VIRTUAL] EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND AN INDIVIDUAL-PATIENT DATA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2357;
In this individual-patient-data meta-analysis of randomized controlled trials with multiple biologics, there were higher rates of induction-of-remission both with biologics and with placebo in early CD, resulting in a treatment-to-placebo effect ratio which is similar across disease durations. No relationships between disease-duration and outcomes was found in UC.
- [VIRTUAL] FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2352;
DI requirement is higher in UC patients and in those with prior anti-TNF exposure. Empirical DI is a relatively effective therapeutic option.
- [VIRTUAL] HISTOLOGICAL INFLAMMATION PREDICTS LOSS OF REMISSION AMONG CROHN’S PATIENTS WITH ENDOSCOPIC REMISSION: A US COHORT ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_572;
Knowledge of disease distribution may also have a role in predicting subsequent LOR. Future research should focus on determining if treatment modification or intensification is effective at preventing LOR in patients with risk factors.
- [VIRTUAL] EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND AN INDIVIDUAL-PATIENT DATA META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_526;
In this individual-patient-data meta-analysis of randomized controlled trials with multiple biologics, there were higher rates of induction-of-remission both with biologics and with placebo in early CD, resulting in a treatment-to-placebo effect ratio which is similar across disease durations. No relationships between disease-duration and outcomes was found in UC.
- [VIRTUAL] FREQUENCY AND EFFECTIVENESS OF EMPIRICAL ANTI-TNF DOSE INTENSIFICATION IN INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW WITH META-ANALYSIS (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_521;
DI requirement is higher in UC patients and in those with prior anti-TNF exposure. Empirical DI is a relatively effective therapeutic option.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
👍 Adds some insight to an area of limited data in IBD....TDM in certolizumab (Twitter) - Jul 18, 2021
- || Clinical, Journal: Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center. (Pubmed Central) - Jul 16, 2021
No AE were reported in patients treated with Golimumab, Certolizumab, Abatacept and Rituximab. An aggressive treatment approach for patients with JIA-associated uveitis ensured a low number of ocular complications with a good safety profile.
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience https://t.co/rf00XNUw1q @IBDJournals @GuiRamosMD (Twitter) - Jul 16, 2021
- || Clinical, Review, Journal: Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. (Pubmed Central) - Jul 16, 2021
Biologic therapy is effective and relatively safe in patients with severe and refractory PUK. Non-anti-TNFα agents appear to be effective in these patients.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] DLQI 0/1 Association with Relative PASI Improvements in Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) () - Jul 15, 2021 - Abstract #IFPA2021IFPA_209;
consistent with previous literature reports. The relationship between skin clearance and QoL observed at Week 48 was maintained at Week 144 among CZP-treated patients with PSO.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] Viral Infections in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Pooled Three‑Year Data () - Jul 15, 2021 - Abstract #IFPA2021IFPA_208;
The relationship between skin clearance and QoL observed at Week 48 was maintained at Week 144 among CZP-treated patients with PSO. Across the CZP in PSO clinical programme, no increased risk was observed for the occurrence of viral infectious disorders for CZP treatment over 144 weeks compared to 16 weeks of exposure.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Clinical data, Journal: Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study. (Pubmed Central) - Jul 14, 2021
This is the first prospective, observational study of an anti-TNF treatment in France. The results confirm the effectiveness and safety profile of certolizumab pegol treatment in patients with RA in a real-world setting.
- || Review, Journal: Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. (Pubmed Central) - Jul 10, 2021
Additional molecules are in an early phase of development. Highly promising biologicals and small oral molecules are the leading edge of the systemic treatment of psoriasis.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Observational data, Journal: Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure. (Pubmed Central) - Jul 10, 2021
P=N/A
No new safety signals were identified, and the safety profile was in line with previous CZP studies. These results support previous clinical trial findings investigating CZP treatment for active RA.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Usability of the Certolizumab Pegol Auto-Injection Device in Australian Patients with Chronic Rheumatic Diseases: Results from a Market Research Study. (Pubmed Central) - Jul 9, 2021
Australian patients with chronic rheumatic disease reported high levels of confidence and satisfaction following initial use of the CZP PFP. The availability of devices with patient-centered design innovations may help overcome barriers to self-injection for improved adherence/outcomes.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Review, Journal: Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis. (Pubmed Central) - Jul 7, 2021
Cyclosporine A might be superior to other pharmacological treatments in efficacy. Amitriptyline and certolizumab pegol were capable of lowering the ICSI as well.
- Cimzia (certolizumab pegol) / Astellas, UCB
[VIRTUAL] UCB Pharma Programme: Optimising the BAD guidelines when treating women of child-bearing age with CIMZIA (certolizumab pegol) () - Jul 5, 2021 - Abstract #BAD2021BAD_525;
Amitriptyline and certolizumab pegol were capable of lowering the ICSI as well. Sponsored Symposium: UCB Pharma
- || Clinical, Journal: Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs. (Pubmed Central) - Jul 2, 2021
Sponsored Symposium: UCB Pharma This multidatabase cohort study found no differences in the risk of NVFs across individual b/tsDMARDs for RA, which provides reassurance to physicians prescribing b/tsDMARDs, especially to patients at high risk of developing NVFs.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Clinical, Journal: Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index. (Pubmed Central) - Jul 2, 2021
Age, BMI, systemic CS use, and disease activity were identified as SIE risk factors in CZP-treated patients. Risk of malignancies was greater in older patients, whereas obesity and male sex were MACE risk factors.
- || Clinical, Journal: Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs). (Pubmed Central) - Jul 1, 2021
Mean PPPM (95% CI) cost in the follow-up was lower for abatacept compared to TNFi ($73 vs. $115; P = 0.042), and other non-TNFi ($73 vs. $125; P = 0.039). There were significantly lower infection-related hospitalizations and associated costs in TNF-experienced RA patients treated with abatacept than TNFis and other non-TNFis.
- | Retrospective data, Journal: Differences in biologics for treating ankylosing spondylitis: the contribution of network meta-analysis. (Pubmed Central) - Jul 1, 2021
There were significantly lower infection-related hospitalizations and associated costs in TNF-experienced RA patients treated with abatacept than TNFis and other non-TNFis. Results from NMA on the use of biologics in AS indicates infliximab emerged as the drug with the highest probability of obtaining ASAS20 response both at 12 and 24 weeks of treatment.